Methimazole and Breastfeeding Safety
Yes, breastfeeding is safe while taking methimazole up to 20 mg per day, and you should continue nursing without interruption. 1
FDA-Approved Safety Profile
The FDA drug label explicitly states that methimazole is present in breast milk, but several studies found no effect on clinical status in nursing infants of mothers taking methimazole 1. A long-term study of 139 thyrotoxic lactating mothers and their infants failed to demonstrate toxicity in infants nursed by mothers receiving methimazole treatment 1.
Evidence-Based Dosing Thresholds
Doses up to 20 mg daily are definitively safe based on the highest-quality prospective research:
At 10 mg daily: All 46 infants maintained completely normal thyroid function (T4, T3, TSH) throughout 12 months of maternal therapy, with the lowest recorded T4 of 108 nmol/L and highest TSH of 4.0 mU/L—both well within normal ranges 2.
At 20 mg daily: All 42 infants remained euthyroid throughout 12 months, with serum methimazole levels in infants measuring less than 0.03-0.035 µg/mL—clinically insignificant amounts 2, 3.
Even at 30 mg daily: 42 infants showed no thyroid dysfunction, though this exceeds typical therapeutic dosing 3.
Infant Monitoring Protocol
Monitor thyroid function at frequent (weekly or biweekly) intervals as specified by the FDA label 1. Specifically:
Measure serum T4, T3, and TSH in the infant before starting maternal therapy, then at 1,2,4,8, and 12 months 2, 4.
Clinical evaluation should assess for signs of hypothyroidism: poor feeding, lethargy, constipation, prolonged jaundice, or delayed growth 2.
Maternal hypothyroidism does not affect infant thyroid function: Even when 16 mothers developed elevated TSH (26-135 mU/L) on methimazole, all their breastfed infants remained euthyroid with TSH values less than 2.6 mU/L 2, 4.
Long-Term Developmental Outcomes
Intellectual development is completely unaffected: At 48-74 months of age, children exposed to methimazole through breast milk showed no difference in IQ scores (107 ± 14 vs. 106 ± 16 on Goodenough test; 103 ± 10 vs. 103 ± 16 on Wechsler test), verbal performance, height, weight, or thyroid antibody titers compared to controls 2.
Clinical Decision Algorithm
Continue breastfeeding if maternal methimazole dose is ≤20 mg daily 1, 2.
Initiate infant thyroid monitoring with baseline T4, T3, TSH before starting maternal therapy 1, 2.
Repeat thyroid function tests at 1,2,4,8, and 12 months 2, 4.
Adjust maternal dose if maternal TSH becomes elevated, but continue breastfeeding as infant thyroid function remains protected 4.
Do not discontinue breastfeeding based on maternal thyroid status alone, as maternal hypothyroidism does not transfer to the infant 4.
Comparison to Propylthiouracil
While propylthiouracil (PTU) transfers into breast milk at even lower amounts (0.025% of maternal dose) 5, methimazole is preferred during lactation because PTU carries significant hepatotoxicity risk for the mother 1. The 2002 ACOG Practice Bulletin states that women treated with either PTU or methimazole can safely breastfeed 5, but methimazole's superior safety profile for the mother makes it the better choice postpartum 1.
Common Pitfalls to Avoid
Do not advise stopping breastfeeding when prescribing methimazole—this is the most common but unnecessary reason for cessation of nursing 6.
Do not confuse pregnancy recommendations with lactation guidance: Methimazole may be avoided in the first trimester of pregnancy due to rare congenital malformations, but this concern does not apply to breastfeeding 1.
Do not switch to PTU for lactation: Unlike pregnancy (where PTU may be preferred in the first trimester), methimazole is the preferred agent during breastfeeding due to maternal safety considerations 5, 1.
Do not rely on maternal thyroid status to predict infant risk: Maternal hypothyroidism induced by methimazole does not cause infant hypothyroidism 4.